| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2020: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2018: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we aimed to develop cell therapy that utilize allogeneic cells for cancer immunotherapy as well as transplantation medicine. Using CRISPER/Cas 9 system or novel retrovirus vector with siRNA, we successfully silenced MHC class I and enforced the expression of HLA-E in allogeneic T cells, resulting in effective escape from the attack from CD8+ T cells as well as NK cells. These T cells were suggested to be highly stealth allogeneic T cells for cancer immunotherapy. Similar results were observed when we utilized a hepatocyte cell line. These data suggests that our technology here is a promising strategy for transplantation medicine with reduced immunosuppressive drugs.
|
